Supernus Pharmaceuticals, Inc. (SUPN)
44.18
-0.70
(-1.56%)
USD |
NASDAQ |
Aug 27, 16:00
44.18
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals EPS Diluted (TTM) : -1.914 for June 30, 2026
EPS Diluted (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.914 |
| March 31, 2026 | -0.512 |
| December 31, 2025 | -0.6839 |
| September 30, 2025 | -0.3408 |
| June 30, 2025 | 1.144 |
| March 31, 2025 | 1.104 |
| December 31, 2024 | 1.318 |
| September 30, 2024 | 1.068 |
| June 30, 2024 | 0.0884 |
| March 31, 2024 | -0.2842 |
| December 31, 2023 | -0.0008 |
| September 30, 2023 | 0.3883 |
| June 30, 2023 | 0.7126 |
| March 31, 2023 | 0.8704 |
| December 31, 2022 | 1.002 |
| September 30, 2022 | 0.6364 |
| June 30, 2022 | 1.001 |
| March 31, 2022 | 1.292 |
| December 31, 2021 | 0.9803 |
| September 30, 2021 | 1.508 |
| June 30, 2021 | 1.855 |
| March 31, 2021 | 2.068 |
| December 31, 2020 | 2.364 |
| September 30, 2020 | 2.409 |
| June 30, 2020 | 2.202 |
| Date | Value |
|---|---|
| March 31, 2020 | 2.162 |
| December 31, 2019 | 2.101 |
| September 30, 2019 | 1.962 |
| June 30, 2019 | 1.942 |
| March 31, 2019 | 1.902 |
| December 31, 2018 | 2.052 |
| September 30, 2018 | 1.833 |
| June 30, 2018 | 1.607 |
| March 31, 2018 | 1.360 |
| December 31, 2017 | 1.06 |
| September 30, 2017 | 1.078 |
| June 30, 2017 | 1.968 |
| March 31, 2017 | 1.828 |
| December 31, 2016 | 1.718 |
| September 30, 2016 | 1.58 |
| June 30, 2016 | 0.48 |
| March 31, 2016 | 0.34 |
| December 31, 2015 | 0.28 |
| September 30, 2015 | 0.24 |
| June 30, 2015 | 0.55 |
| March 31, 2015 | 0.59 |
| December 31, 2014 | 0.19 |
| September 30, 2014 | -0.56 |
| June 30, 2014 | -1.73 |
| March 31, 2014 | -2.70 |
EPS Diluted (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (TTM) Benchmarks
| Indivior Pharmaceuticals, Inc. | 2.815 |
| Pfizer Inc. | 0.7552 |
| Amphastar Pharmaceuticals, Inc. | 1.706 |
| Collegium Pharmaceutical, Inc. | 1.234 |
| Bristol Myers Squibb Co. | 4.539 |